Top

Digestive Diseases and Sciences

Published in:

01-09-2020 | Infliximab | Correspondence

Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of “Non-medical Switch”

Authors: Angelo Viscido, Giovanni Latella

Published in: Digestive Diseases and Sciences | Issue 9/2020

Excerpt

Dear Editor, …

Bernard EJ, Fedorak RN, Jairath V. Systematic review: non-medical switching of infliximab to CT-P13 in inflammatory bowel disease. Dig Dis Sci. 2020; https://doi.org/10.1007/s10620-019-06036-0.CrossRefPubMedPubMedCentral

Scott FI. Infliximab versus biosimilars for IBD: is it better to fight than switch? Dig Dis Sci. 2020; https://doi.org/10.1007/s10620-020-06283-6.CrossRefPubMed

McKinnon RA, Cook M, Liauw W, et al. Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs. 2018;32:27–52.CrossRef

European Medicines Agency. Biosimilars in the EU—Information guide for healthcare professionals; 2019. Available at: https://www.ema.europa.eu/en/documents/leaflet/biosimilars-eu-information-guide-healthcare-professionals_en.pdf. Accessed May 9 2020.

Food and Drug Administration. Biosimilar and Interchangeable Products in the United States: Scientific Concepts, Clinical Use, and Practical Considerations; 2018. Available at: https://www.fda.gov/media/122832/download. Accessed May 9 2020.

Fiorino G, Caprioli F, Daperno M, et al. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Dig Liver Dis. 2019;51:632–639. https://doi.org/10.1016/j.dld.2019.02.004.CrossRefPubMed

Fleischmann R, Jairath V, Mysler E, et al. Nonmedical switching from originators to biosimilars: does the nocebo effect explain treatment failures and adverse events in rheumatology and gastroenterology? Rheumatol Ther. 2020;7:35–64. https://doi.org/10.1007/s40744-019-00190-7.CrossRefPubMedPubMedCentral

Kaplan GG, Ma C, Seow CH, et al. The argument against a biosimilar switch policy for infliximab in patients with inflammatory bowel disease living in Alberta. J Can Assoc Gastroenterol. 2020; https://doi.org/10.1093/jcag/gwz044.CrossRefPubMedPubMedCentral

Bhat S, Altajar S, Shankar D, et al. Process and clinical outcomes of a biosimilar adoption program with infliximab-dyyb. J Manag Care Spec Pharm. 2020;26:410–416. https://doi.org/10.18553/jmcp.2020.26.4.410.CrossRefPubMed

Title: Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of “Non-medical Switch”
Authors: Angelo Viscido
Giovanni Latella
Publication date: 01-09-2020
Publisher: Springer US
Keywords: Infliximab
Chronic Inflammatory Bowel Disease
Published in: Digestive Diseases and Sciences / Issue 9/2020
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-020-06423-y

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Non-medical Switching of Infliximab to CT-P13 Biosimilar in Inflammatory Bowel Disease: A Focus on the Definition of “Non-medical Switch”

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 9/2020

Correction to: Celiac Disease Screening for High-Risk Groups: Are We Doing It Right?

Pyoderma Gangrenosum in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

A Novel Method for the Prevention and Treatment of Small-for-Size Syndrome in Liver Transplantation

Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality

Like a “Rolling” Gallstone: Cholecystoduodenal Fistula as Evidence of Gallstone Ileus

Early Rapid Fluid Therapy Is Associated with Increased Rate of Noninvasive Positive-Pressure Ventilation in Hemoconcentrated Patients with Severe Acute Pancreatitis

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page